A new study has found no evidence of widespread brain inflammation in patients suffering from prolonged symptoms after Covid-19 infection. In fact, the most severe long Covid symptoms were associated with increased brain activity in regions involved in mood and emotion.
Researchers at the University of Turku, Finland, used advanced brain imaging techniques to investigate whether long Covid patients with persistent symptoms show signs of brain inflammation.
(Source: University of Turku)
Turku/Finland – A new brain imaging study has found no evidence of widespread brain inflammation in patients suffering from prolonged symptoms after Covid-19 infection. Instead, the most severe long Covid symptoms were associated with increased brain activity in regions involved in mood and emotion.
Long Covid has been suspected to involve persistent brain inflammation following Sars-Cov-2 infection, potentially explaining symptoms such as fatigue, cognitive impairment, anxiety, and depression. While previous studies have suggested this possibility, direct evidence has been limited.
Researchers at the University of Turku, Finland, used advanced brain imaging techniques to investigate whether long Covid patients with persistent symptoms show signs of brain inflammation.
“We did not observe evidence of widespread brain inflammation in patients with long Covid when compared to healthy controls,” says Professor of Neuroimmunology and Inflames Research Flagship group leader Laura Airas, who led the study.
The study included 14 individuals with long Covid, 11 healthy controls, and 13 patients with multiple sclerosis (MS), a neurological disease known to involve brain inflammation.
All participants underwent PET imaging sensitive to neuroinflammation, along with magnetic resonance imaging (MRI) to assess brain structure and white matter changes. Blood samples were analyzed for biomarkers reflecting neuronal and glial damage.
Compared to MS patients, individuals with long Covid showed significantly lower inflammatory activity in the brain’s white matter. No differences in markers of brain inflammation or neurodegeneration were observed between long Covid patients and healthy controls.
Brain inflammation may be present early after infection
Clear signs of brain inflammation have previously been observed in neuropathological studies of severe acute Covid-19. In the current study, individuals scanned within 16 months of infection showed higher white matter inflammatory activity compared to those with longer disease duration.
According to Airas, this suggests that inflammation may be more prominent during the early phase of the disease and decrease over time.
An important finding of the study was that higher levels of depression and anxiety, as well as lower quality of life, were associated with increased cellular activity in the hippocampus and amygdala. They are brain regions involved in memory, emotional regulation, and stress responses.
These findings suggest that altered cellular activation in emotion-regulating brain regions may be linked to symptom severity in some patients with long Covid.
Brain inflammation may be present early after infection
The researchers note that the findings refine our understanding of long Covid and challenge the idea that persistent brain inflammation is the primary driver of prolonged symptoms in all patients. Instead, the results point to a more complex disease profile, where inflammatory changes may be strongest right after infection and diminish over time.
Long Covid is a recognized condition affecting millions of people worldwide, with symptoms that can persist for months or even years after the initial infection.
The researchers suggest that patients with prolonged symptoms may benefit more from treatments targeting stress and emotional regulation rather than therapies aimed solely at reducing inflammation.
“This study highlights the need to continue investigating the complex biological mechanisms underlying long Covid. Understanding these processes is essential for developing targeted treatments,” notes Airas.
The study by Airas and colleagues has been published in the Journal of Neurology.
Inflames Flagship is a joint initiative of the University of Turku and Åbo Akademi University, Finland. The goal of the Flagship is to integrate the immunological and immunology-related research activities to develop and exploit new diagnostic and therapeutic tools for personalized medicine. Inflames is part of the Research Council of Finland´s Flagship Programme.
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.